ON DEMAND
KEYNOTE: Next Generation for Cell Therapies
Carl June, University of Pennsylvania
EXECUTIVE PANEL: Exploring the hurdles that are in place whilst targeting solid tumors; and how to clear the route for an “off the shelf” therapy
MODERATOR: Nick Serseni, EY
Peter Emtage, Kite Pharma Inc
Pascal Touchon, Atara Biotherapeutics
Stefan Wildt, Takeda Pharmaceuticals
HEADLINE KEYNOTE: Unlocking the power of data and technology to deliver on the promise of cell and gene therapies
Aldai Goldberg, EY
David C. Rhew, Microsoft
Orlando Serani, Johnson & Johnson
Sarah Dye, Optum
CAR-T R&D - PRESENTATION: Cartitude-1 Study with Updates in Toxicity & Management
Deepu Madduri, Mount Sinai Hospital
VEIN TO VEIN - PRESENTATION:Transitioning from outsourcing to in-house manufacturing facilities and accessing cell therapy manufacturing models
Knut Niss, Mustang
CLINICAL & COMMERCIALIZATION -PRESENTATION: Clinical use of CAR-T for DLBCL
David Miklos, Stanford University
NATURAL KILLER CELLS -PRESENTATION: Natural Killer cells in cancer immunotherapy
Jeffrey Miller, University of Minnesota
CAR-T R&D - PRESENTATION: Technology (and) Innovation to support the global scaleup challenges on the horizon
Steven Lynum, PHC Corporation (Japan)
Carl Radosevich, PHC Corporation
CLINICAL & COMMERCIALIZATION -PRESENTATION: Non-viral technologies for development and manufacture of next generation cell therapies
Shirley O’Dea, Avectas
CAR-T R&D - PRESENTATION: Using Red Cell Therapeutics to Enhance Antitumor Immune Reponses
Chris Coughlin, Rubius Therapeutics
VEIN TO VEIN - PRESENTATION: Guidelines for cell characterisation and cell function
John T Elliot, NIST
CLINICAL & COMMERCIALIZATION - PRESENTATION: Large B cell lymphoma long term safety trials
Caron Jacobson, Dana Faber Cancer Institute
NATURAL KILL CELLS - PRESENTATION: Maximising the therapeutic effect of allogeneic natural killer cells
James Trager, Nkarta
Ivan Chan, Nkarta
PRESENTATION: Scale-Out of Commercially Viable Autologous CAR T Cell Manufacturing
Fred Koller, Miltenyi Biotec
PRESENTATION: Development of autologous cellular immunotherapies optimizing personalized, tumor directer TILs
Maria Fardis, Iovance Biotherapeutics
CAR-T R&D PRESENTATION: Enhancing CAR-T with small molecules to regulate for enhanced activity against solid tumor
Steve Shamah, Obsidian Therapeutics
VEIN TO VEIN PRESENTATION: CMC project management for cell and gene therapies
Moderator: Rachit Jain, Werum IT Solutions America
Seshu Tyagarajan, Novartis Pharmaceuticals
CLINICAL & COMMERCIALIZATION PRESENTATION: Development of TCR T cell Therapies for Treatment of Solid Tumors
Paul Stead, Adaptimmune
VEIN TO VEIN PRESENTATION: Next Generation Workforce Development for Cell Therapy Manufacturing
Haro Hartounian, BioPharma Innovation
CLINICAL & COMMERCIALIZATION PRESENTATION: Artificial intelligence for tumor specific neoantigen identification
Matt Davis, Gritstone Oncology
CAR-T R&D PRESENTATION: Molecular Characterization for CAR-T Cell Therapy: A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Erin Piazza,NanoString Technologies
CLINICAL & COMMERCIALIZATION PRESENTATION: Lentiviral vectors: towards more cost-effective, scalable and regulatory-compliance processes.
Dr Juan Carlos Ramirez, VIVEbiotech
Interactive Focused Round Table 1: Cell homing to target solid tumors
Robert Koechl, King's College London
Interactive Focused Round Table 2: Development of functional lymphocytes from human pluripotent stem cells
Dan Kaufman, University of California
Interactive Focused Round Table 3: Targeting glioblastoma through the use of cell therapies
Andrew Speigel, Global Colon Cancer Association
PRESENTATION: Fusion Proteins to bridge CAR19 T cell and tumor cells
Paul Rennert, Aleta Biotherapeutics Inc
PRESENTATION: Vd1 Gammadelta T Cells
Alice Brown, Gammadelta Therapeutics
PRESENTATION: Challenges of Vector Production in Support of Phase I Clinical Trials
Steven Feldman, Stanford University
PRESENTATION: Best practice REMS development
Larissa Lapteva, FDA
PRESENTATION: Adoptive cell therapy using engineered TAC T-cells to invade solid tumors
Paul Lammers, Triumvira
PRESENTATION: TRuC®-T Cells: Harnessing The Full T Cell Receptor without HLA Restriction for Cancer Therapy
Robert Hofmeister, TCR2 Therapeutics
PRESENTATION: Digital Solution for Cell and Gene Therapy with Lessons learned
Rachit Jain, Werum
Ryan Hamilton, Werum
PANEL: Allogeneic Therapies
Moderator: Peggy Sotiropoulou, Celyad Oncology
Alan Trounson, CEO, Cartherics